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Abstract
Human Cytomegalovirus (HCMV) infection induces several metabolic activities that have been found to be important for
viral replication. The cellular AMP-activated protein kinase (AMPK) is a metabolic stress response kinase that regulates both
energy-producing catabolic processes and energy-consuming anabolic processes. Here we explore the role AMPK plays in
generating an environment conducive to HCMV replication. We find that HCMV infection induces AMPK activity, resulting in
the phosphorylation and increased abundance of several targets downstream of activated AMPK. Pharmacological and RNA-
based inhibition of AMPK blocked the glycolytic activation induced by HCMV-infection, but had little impact on the
glycolytic pathway of uninfected cells. Furthermore, inhibition of AMPK severely attenuated HCMV replication suggesting
that AMPK is an important cellular factor for HCMV replication. Inhibition of AMPK attenuated early and late gene expression
as well as viral DNA synthesis, but had no detectable impact on immediate-early gene expression, suggesting that AMPK
activity is important at the immediate early to early transition of viral gene expression. Lastly, we find that inhibition of the
Ca2+-calmodulin-dependent kinase kinase (CaMKK), a kinase known to activate AMPK, blocks HCMV-mediated AMPK
activation. The combined data suggest a model in which HCMV activates AMPK through CaMKK, and depends on their
activation for high titer replication, likely through induction of a metabolic environment conducive to viral replication.
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Introduction
Upon infection, viruses must create a cellular environment
conducive to viral replication. While there are many different
aspects of this virally-induced environment, a critical component of
this cellular reprogramming is the diversion of cellular resources such
as energy and molecular building blocks to the production of viral
progeny. Numerous viruses, ranging from small, non-enveloped
RNA viruses to large enveloped DNA viruses have been reported to
target the host-cell metabolic machinery [1–9]. This suggests that
cellular metabolic function is a key virus-host interaction.
Human cytomegalovirus (HCMV), a member of the betaher-
pesvirus family, is a major cause of birth defects upon congenital
infection as well as morbidity in immunosuppressed populations
[10–12]. HCMV has been found to cause drastic changes to the
host cell metabolic network upon infection, increasing the
concentrations of select glycolytic enzymes, the steady state levels
of glycolytic metabolites, and the fluxes through glycolysis and the
TCA cycle [13–14]. Though the exact mechanisms through which
HCMV induces glycolytic activation are not clear, it has recently
been shown that virally-mediated activation of glycolysis can be
blocked through inhibition of CaMKK and that HCMV infection
induces the expression of the Glut4 transporter [15–16]. Here we
explore the role of the AMP-activated protein kinase (AMPK)
during HCMV replication and HCMV-mediated glycolytic
activation.
AMPK is a heterotrimeric, serine-threonine kinase that
functions as a major energy regulator for the cell. Low ATP
levels result in increased concentrations of AMP through the
action of adenylate kinase [17]. These increased AMP concentra-
tions induce AMP binding to AMPK and subsequent stimulation
of AMPK activity, primarily through either LKB1 or CaMKK-
dependent phosphorylation [18–21]. Upon activation, AMPK
works to restore the ATP pool by activating ATP-producing
pathways while simultaneously inhibiting ATP-consuming path-
ways [22–23]. One pathway positively regulated by AMPK is
glycolysis. Upon AMPK activation, glycolysis can be upregulated
through several mechanisms. AMPK targets numerous key
glycolytic enzymes including glucose transporters (Glut1 and
Glut4), hexokinase and PFK-2, to increase glycolytic flux [23–26].
Here we show that AMPK activity is increased throughout viral
infection relative to mock-infected fibroblasts. Additionally, high-
titer HCMV replication requires activated AMPK as pharmaceu-
tical or RNAi-based inhibition of AMPK severely attenuates the
production of viral progeny. Consistent with a role in glycolytic
activation, AMPK inhibition also leads to an attenuation of
HCMV-induced glycolytic flux. These results suggest that AMPK
is a critical cellular protein targeted by HCMV infection.
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Results
AMPK activity increases upon HCMV infection
To determine if AMPK might be responsible for the metabolic
induction observed during HCMV infection, we analyzed mock or
HCMV-infected extracts for AMPK activity using a well described
in vitro AMPK activity assay [27]. To help verify the specificity of
the measured AMPK activity, we also performed assays in the
presence of Compound C, a specific AMPK inhibitor [28]. At
24 h post-infection both mock and HCMV-infected cells exhibited
similar amounts of AMPK activity (Fig. 1). Compound C
treatment suppressed the observed AMPK activity to a back-
ground level of ,2000 CPM, which was a consistent background
level at all time points examined (Fig. 1). At later time points, i.e.
48 and 72 h post-infection, the AMPK activity associated with
mock-infected fibroblasts fell significantly to background levels
(Fig. 1). In contrast, the AMPK activity associated with HCMV-
infected lysates increased over this time frame with much greater
AMPK activity levels observed in HCMV-infected lysates than in
mock-infected lysates at the same time points (Fig. 1). These results
indicate that HCMV induces AMPK activity upon infection.
Previously we have found that HCMV infection increases the
total levels of the fatty acid biosynthetic enzyme, acetyl-CoA
carboxylase (ACC1) as well as the amount of phosphorylated
ACC1 [29]. AMPK has been shown to phosphorylate ACC1 at
Ser79, resulting in decreased ACC1 activity with the end-result
being inhibition of fatty acid biosynthesis and conservation of ATP
[17]. To determine if activated AMPK increases levels of
phosphorylated ACC1 in MRC-5 fibroblasts, we treated cells
with an AMPK activator, AICAR [30]. AICAR treatment resulted
in substantial increases in the abundance of phosphorylated ACC
(Fig. 2A), consistent with activation of AMPK. Subsequently, we
analyzed the levels of total ACC1 and Ser79 phosphorylated
ACC1 in the presence of the AMPK inhibitor, Compound C,
during HCMV infection. At 24 h post-infection, HCMV-infected
lysates contained more Ser79-phosphorylated ACC1 than mock-
infected lysates (Fig. 2B). At this time, treatment with Compound
C reduced the levels of Ser79-phosphorylated ACC1 to the levels
found in uninfected cells, indicating that AMPK might be
responsible for the increased abundance of phosphorylated
ACC1 (Fig. 2B). At 48 and 72 h post-infection, treatment with
Compound C reduced the levels of Ser79-phosphorylated ACC1
in HCMV infected lysates but also decreased the levels of total
ACC1 (Fig. 2B). Using densitometry, the relative signal ratios of
pACC to ACC in the HCMV infected lysates were examined
(Fig. 2B). Treatment with Compound C had the largest impact on
the pACC/ACC ratio at 24 hpi, reducing it ,10-fold. At
subsequent times post infection, Compound C reduced the
pACC/ACC ratio at every time point, consistent with decreased
phosphorylation, albeit to a much lesser extent than observed at 24
hpi (Fig. 2B). While the decreases in phospho-ACC1 relative to
total ACC1 upon Compound C treatment are consistent with
inhibition of AMPK-mediated phosphorylation of ACC1, Com-
pound C treatment also impaired the HCMV-induced accumu-
lation of total ACC1 suggesting that Compound C treatment
could be impacting normal HCMV infection.
Previous reports indicate that HCMV infection induces the
levels of the Glut4 glucose transporter and the tuberous sclerosis
protein (TSC1), a negative regulator of mTOR signaling [15,31].
Activated AMPK has been shown to increase Glut4 expression
[32] as well as TSC1 levels through prevention of proteosome
mediated TSC1 degradation [33–34]. Our results indicating that
HCMV infection induces AMPK activity suggest the possibility
that the induction of these proteins during HCMV infection may
result from increased AMPK activity. As previously reported [31],
in the absence of inhibitor treatment, HCMV infection has little
impact on TSC1 levels at 24 h post-infection but significantly
increased the levels of TSC1 at 48 h post-infection and 72 h post-
infection (Fig. 2C). Treatment of HCMV-infected cells with
Compound C substantially reduced the levels of TSC1 at all time
points compared to DMSO treated controls (Fig. 2C) suggesting
that AMPK activity is necessary for HCMV-mediated induction of
TSC1 levels. As was reported previously [15], we also observed
increases in Glut4 in HCMV-infected cells as compared to mock-
infected cells at 48 and 72 h post-infection (Fig. 2C). Treatment
with Compound C inhibited this induction of Glut4 levels (Fig. 2C)
suggesting that AMPK activity is important for the viral induction
of Glut4 expression. Taken together, our results indicate that
HCMV-infection activates AMPK which in turn is necessary for
the induction of TSC1 and Glut4 levels.
AMPK can be activated by phosphorylation at residue Thr172
mediated by either LKB1 or CaMKK [17]. As shown in
Figure 1. AMPK is activated during HCMV infection. Serum-
starved MRC-5 human fibroblasts were mock- infected or infected with
HCMV (MOI = 3). After adsorption, cells were treated with DMSO or the
AMPK inhibitor, Compound C (5 mM). At 24, 48 and 72 h post infection
cells were harvested in lysis buffer and the resulting lysates were
assayed for AMPK activity using the SAMS peptide as a substrate. Values
are mean + SE (n = 2).
doi:10.1371/journal.ppat.1002502.g001
Author Summary
Human Cytomegalovirus (HCMV) is a ubiquitous human
pathogen that is a major cause of birth defects. HCMV can
also cause severe disease in immunocompromised indi-
viduals including transplant recipients, leukemia patients
and those infected with HIV. It is clear that upon infection,
HCMV takes control of numerous cellular processes that
are important for the virus to generate the next round of
infectious virions. We have previously found that upon
infection, HCMV reprograms the metabolic activity of the
host-cell. Here, we find that this metabolic reprogramming
largely depends on the viral activation of a cellular protein
called the AMP-activated protein kinase (AMPK). AMPK is a
central regulator of cellular energy production that is
typically only activated when cellular energy stores are
very low. Our results indicate that HCMV-mediated
activation of AMPK is necessary to flip the metabolic
switch thereby driving host-cell metabolic activation and
viral replication. As inhibition of AMPK blocked viral
replication, and had little impact on uninfected host-cell
metabolism, targeting AMPK could have therapeutic
potential to treat HCMV-associated disease.
Viral Targeting of AMPK
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Figure 2D, HCMV-infected extracts contained a higher level of
total and phosphorylated AMPK then mock extracts at 24, 48 and
72 h post-infection. In both mock and HCMV-infected cells, the
amount of Thr172-phosphorylated AMPK appeared to be the
greatest at 24 h post-infection and subsequently declined as
infection progressed (Fig. 2D). For uninfected cells, this decline in
Thr172-phosphorylated AMPK correlated with the decreased
AMPK activity observed in cellular lysates (Fig. 2D). For the
HCMV-infected cells, the increase in AMPK activity observed as
infection progressed did not correlate with the levels of Thr172-
phosphorylated AMPK although the levels of total AMPK
remained elevated. This combination of increased abundance of
total AMPK and increased AMPK Thr172 phosphorylation likely
contribute to the observed increases in AMPK activity during
HCMV infection, although as AMPK is reported to be regulated
by multiple phosphorylation events [35–37], other mechanisms of
activation cannot be ruled out. Treatment of cells with Compound
C did not appreciably impact AMPK Thr172 phosphorylation
(Fig. 2D), not surprising given that Compound C inhibits AMPK
through competitive inhibition at its ATP binding site [28]. Taken
together, our results suggest that HCMV activates AMPK during
infection likely in part due to an increase in both the
phosphorylation at Thr172 as well as the total abundance of
AMPK.
Inhibition of AMPK attenuates HCMV-mediated glycolytic
activation
AMPK is a central metabolic regulator whose activation can
activate glycolysis by targeting multiple steps within the glycolytic
pathway including glucose uptake and phosphofructokinase
activity [17]. To determine if AMPK is important for the
induction of glucose import by HCMV, we treated mock or
HCMV-infected fibroblasts with Compound C and analyzed
glucose import using a radioactive glucose analog. Consistent with
previous reports [15,26], HCMV infection induced glucose uptake
greater than 5-fold compared to mock-infected cells (Fig. 3A).
Treatment with Compound C almost completely reversed this
increase (Fig. 3A). Compound C had a negligible impact on
glucose uptake in mock-infected fibroblasts (Fig. 3A). These data
indicate that HCMV relies heavily on AMPK activity to activate
glucose import whereas AMPK is not critical for glucose uptake in
uninfected fibroblasts.
To further analyze how activation of AMPK contributes to
HCMV-mediated glycolytic activation, we measured the rate of
glycolytic labeling after treatment with Compound C using 13C-
labeled glucose as a metabolic tracer. Specifically, utilizing LC-
MS/MS we measured the rate of 13 C-fructose bisphosphate
accumulation, a central glycolytic metabolite, after pulse with 13C-
glucose. Treatment with Compound C led to an approximate 2-
fold decrease in 13C-labeled FBP accumulation in HCMV-infected
fibroblasts (Fig. 3B). In contrast, inhibition of AMPK had little
impact on the labeling rate of mock-infected fibroblasts (Fig. 3B).
Lastly, we measured how inhibition of AMPK impacted the most
downstream glycolytic phenotype, accumulation of lactate in the
media. Treatment with Compound C substantially reduced lactate
secretion in HCMV-infected fibroblasts, but not mock-infected
fibroblasts (Fig. 3C). In all of the glycolysis assays tested, the
inhibition of glycolytic flux upon Compound C treatment was
specific for HCMV-infected cells. This suggests that AMPK is
important for HCMV-induced glycolytic activation, but does not
contribute appreciably to the glycolytic rate in uninfected
fibroblasts, which is consistent with AMPK’s described role as a
stress-induced metabolic regulator [17].
Addition of Compound C immediately following adsorption
blocked HCMV-mediated activation of glycolysis (Fig. 3A–C). To
determine whether this glycolytic activation was sensitive to
AMPK inhibition after the establishment of infection, we treated
cells with Compound C at 24 hpi, a time at which immediate early
gene expression is peaking, early genes are being expressed and
viral DNA replication is initiating [38]. Subsequently, we
Figure 2. Impact of AMPK inhibition on AMPK substrate accumulation during HCMV infection. (A) MRC-5 human fibroblasts were
incubated in glucose free media with DMSO (-) or AICAR for 1h or 2.5 h prior to blotting with antibodies specific for pSer79-specific ACC1, total ACC1,
or tubulin. (B-D) Serum-starved MRC-5 human fibroblasts were mock infected or infected with HCMV (MOI = 3). After adsorption, cells were treated
with the AMPK inhibitor, Compound C (5 mM), or DMSO (-). Cells were harvested at 24, 48 and 72 h post infection and analyzed by Western blot with
antibodies specific for pSer79-specific ACC1, total ACC1 and tubulin in (B), TSC1, Glut4 and tubulin in (C), and pThr172-specific AMPK, total AMPK and
tubulin (D). Relative pACC/ACC signal ratios in (B) were estimated during HCMV infection for DMSO and Compound C-treated cells using
densitometry and subsequently normalized to the ratio of the DMSO control sample.
doi:10.1371/journal.ppat.1002502.g002
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measured lactate excretion into the media from 40-58 hpi, and
from 58–76 hpi. As compared to a DMSO-treated control,
treatment with Compound C immediately following adsorption
resulted in a ,40% reduction in lactate excretion (Fig. 3D).
Treatment of cells at 24 hpi resulted in a ,20% reduction in
lactate excretion whether measured from 40–58 or 58–76 hpi
(Fig. 3D). These results suggest that while HCMV-mediated
activation of glycolysis is more sensitive to AMPK inhibition at the
very beginning of infection, the induction of glycolysis is still
attenuated when AMPK is inhibited during an HCMV infection
that has already been established.
Inhibition of AMPK attenuates production of HCMV viral
progeny
Given that HCMV-infection induces AMPK activity (Fig. 1),
and that AMPK activity is important for HCMV-mediated
glycolytic activation (Fig. 3), we next tested if AMPK inhibition
impacts viral replication. We treated fibroblasts with DMSO or
two different concentrations of Compound C, and analyzed the
production of viral progeny by plaque assay. Treatment with
increasing concentrations of Compound C resulted in a dose-
dependent decrease in viral titers. A greater than 20-fold defect in
production of viral progeny was observed at 2.5 mM Compound C
and a greater than 1000-fold defect was observed in cells treated
with 5 mM Compound C (Fig. 4A). To exclude the possibility of
toxicity from drug treatment, we also performed a Live/Dead
assay which stains live cells green based on their esterase activity
and stains the nucleic acids of dead cells red based on the
breakdown of membrane integrity. Treatment with Compound C
at the highest concentration (5 mM, Fig. 4B) resulted in little to no
red staining in both mock- and HCMV-infected fibroblasts ( ,1%)
with ubiquitous green staining (.99%) suggesting that Compound
C treatment is not toxic to MRC-5 fibroblasts up to a
concentration of 5 mM. These results suggest that AMPK activity
is important for HCMV replication and that inhibition of AMPK
does not induce significant toxicity in MRC-5 fibroblasts.
We were interested in determining at what point during the
infectious cycle AMPK activity might be required for high-titer
HCMV replication. To address this issue, we treated cells with
Compound C at various points post-infection and analyzed viral
replication. Addition of Compound C at 24 and 48 hrs resulted in
a greater than 10 and 5-fold reduction in the production of viral
progeny, respectively, compared to DMSO treated (Fig. 4C).
These are significant reductions in viral yield and suggest that
AMPK is important throughout the duration of HCMV infection
for peak viral production. However, the difference in viral growth
Figure 3. Inhibition of AMPK blocks HCMV-induced glycolytic activation. Serum-starved MRC-5 human fibroblasts were mock infected or
infected with HCMV (MOI = 3). After adsorption, cells were treated with the AMPK inhibitor Compound C (5 mM) or DMSO. (A) At 48 h post infection,
cells were labeled with [14C]-deoxyglucose for 5 min and harvested for scintillation counting as described in the materials and methods. (B) At 48 h
post infection, cells were labeled for 1 min with [13C] glucose containing DMEM, quenched with cold methanol, and processed for LC-MS/MS to
measure the accumulation of [13C] fructose bisphosphate. All values are means + SE (n = 2). (C) At 40 h post infection, fresh media was added to all
cells. At 58 h post infection, media was removed from mock and HCMV-infected fibroblasts and lactate secretion into the media over the 18 hr time
frame was analyzed. All values are means + SE (n = 6). (D) Serum-starved MRC-5 human fibroblasts were HCMV infected (MOI = 3) and Compound C
(5 mM) was added either immediately after adsorption (0) or 24 h post infection. Lactate excretion was measured from 40–58 hpi or from 58–76 hpi.
Values are shown as the percent of the HCMV-infected, DMSO treated control and are means + SE (n$3).
doi:10.1371/journal.ppat.1002502.g003
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between treatment at adsorption and treatment at 24 h is large
(,100-fold, Fig. 4C), suggesting that the major requirement for
AMPK activity occurs during the first 24 h of infection. Addition
of Compound C at 72 hrs post-infection had a negligible impact
on HCMV viral growth (Fig. 4C). This suggests that AMPK
activity is not necessary during the late stages of growth.
Furthermore, this lack of inhibition when added at 72 hpi suggests
that Compound C is not blocking infectious HCMV production
through some artifactual interaction with newly produced HCMV
virions.
Impact of pharmaceutical AMPK inhibition on the viral
life cycle
With the observation that Compound C treatment decreases
HCMV viral titers, we were interested in investigating how this
inhibition impacted other aspects of the viral life cycle. We
performed Western blot analysis and quantitative real-time PCR
(qPCR) to determine the effects of Compound C on viral protein
accumulation and viral DNA replication, respectively. The
expression of the immediate early protein, IE1, was largely
unaffected by Compound C treatment (Fig. 5A), however a large
decrease in the abundance of the early protein UL44 and the late
protein pp28 was observed (Fig. 5A). These results suggest that
AMPK is required for the transition from the immediate early to
the early stages of infection. As many early genes are involved in
the regulation of viral DNA replication, we hypothesized that this
defect in early gene expression could result in decreased viral DNA
replication. As shown in Figure 5B, when virally infected
fibroblasts are treated with Compound C, a marked decrease in
viral DNA accumulation is observed, most notably at 48 and 72 h
post-infection. These findings suggest that AMPK inhibition
affects the viral life cycle at early stages of infection and inhibits
viral DNA replication.
Figure 4. Pharmaceutical inhibition of AMPK attenuates HCMV viral replication. (A) Serum-starved MRC-5 human fibroblasts were mock-
infected or infected with HCMV (MOI = 3). After adsorption, cells were treated with the AMPK inhibitor, Compound C (CC), at concentrations of 2.5 mM
or 5 mM or with DMSO alone. Cells were harvested at 96 h post infection and the production of infectious viral progeny was measured by a standard
plaque assay. Values are means + SE (n = 3). (B) Analysis of the potential toxicity of Compound C treatment. Confluent MRC-5 fibroblasts were mock
infected or infected with HCMV (MOI = 3). After adsorption, cells were treated with 5 mM Compound C (CC). At 72 h post infection, cell viability was
measured via a Live/Dead cell viability assay. Green indicates the presence of esterase activity associated with viable cells, while red indicates loss of
cellular membrane integrity associated with cell death. As a positive control for staining of a breakdown in membrane integrity, cells were briefly
treated with ethanol. (C) Serum-starved MRC-5 human fibroblasts were HCMV-infected (MOI = 3). Compound C was added at adsorption (0), 24, 48 or
72 h post infection. As a viral growth control, DMSO was added to HCMV infected cells at adsorption. All samples were harvested at 96 h post
infection and the production of infectious viral progeny was measured by a standard plaque assay. Values are means + SE (n = 2).
doi:10.1371/journal.ppat.1002502.g004
Figure 5. Impact of AMPK pharmaceutical inhibition on viral
protein and DNA accumulation. (A) Analysis of the impact of AMPK
inhibition on viral protein accumulation. Serum-starved MRC-5 human
fibroblasts were mock infected or infected with HCMV (MOI = 3). After
adsorption, cells were treated with the AMPK inhibitor Compound C
(CC, 5 mM) or DMSO alone (-). Cells were harvested at 6, 24, 48 and 72 h
post infection and analyzed by Western blotting with antibodies
specific for IE1, UL44, pp28 and tubulin. (B) Analysis of the impact of
AMPK inhibition on viral DNA accumulation. Serum-starved MRC-5 cells
were mock infected or infected with HCMV (MOI = 3). After adsorption,
cells were treated with the AMPK-specific inhibitor Compound C (CC,
5 mM) or DMSO. Viral DNA was extracted from cells that were harvested
at 24, 48, and 72 h post infection and processed for qPCR analysis of
viral DNA accumulation. Values are means + SE.
doi:10.1371/journal.ppat.1002502.g005
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RNAi-mediated AMPK inhibition attenuates HCMV
replication and HCMV-mediated activation of glycolysis
The finding that pharmaceutical inhibition of AMPK attenuates
viral replication and HCMV-induced glycolytic flux suggests that
AMPK plays an important role during viral infection. Despite
reports that Compound C is a specific inhibitor of AMPK [28], the
possibility for off-target effects is always an issue with pharmaceu-
tical inhibitors. To confirm the importance of AMPK for HCMV
replication, we employed an AMPK-specific RNAi to decrease
AMPK expression during infection. Transfection of RNAi specific
for AMPK resulted in an ,40% reduction in AMPK abundance
in both mock and HCMV-infected fibroblasts at 24 h post-
infection in comparison to control RNAi transfected cells (Fig. 6A).
Analysis of AMPK activity indicated that transfection of AMPK-
specific RNAi prior to HCMV infection reduced AMPK activity
by approximately 50%, comparable to mock levels (Fig. 6B).
AMPK-specific RNAi had a much smaller impact on the AMPK
activity of mock-infected cells (Fig. 6B), consistent with a relative
lack of AMPK activity in mock-infected cells to start with. Analysis
of media lactate accumulation indicated that AMPK-specific
RNAi ablated the HCMV-mediated induction of lactate excretion,
but had little impact on the lactate excretion of mock-infected cells
(Fig. 6C). Analysis of how RNAi-mediated AMPK inhibition
impacted viral replication indicated a greater than 250-fold
reduction in viral progeny production as compared to control
cells (Fig. 6D). In total, these results confirm our findings that
AMPK is a critical cellular factor required both for HCMV-
mediated glycolytic induction as well as for high-titer replication.
The impact of CaMKK inhibition on AMPK activity
Previously, we have shown that glycolysis is upregulated upon
HCMV infection, and that CaMKK appears to be required for
both productive viral replication and virally-induced glycolytic flux
[16]. CaMKK has been shown to be involved in the regulation of
AMPK activity under various conditions [18,39]. Given the
observation that AMPK appears to be important for both
productive viral replication and HCMV-induced glycolytic flux
as well, it seemed likely that CaMKK could be responsible for
activating AMPK during HCMV infection. In order to determine
the importance of CaMKK for AMPK activation, we used the
CaMKK-specific inhibitor STO-609 to treat fibroblasts and
subsequently analyzed the impact on AMPK activity. As shown
in Figure 7A, inhibition of CaMKK blocked the induction of
AMPK activity during HCMV infection. Importantly, it has been
previously reported that STO-609 treatment at a similar dos-
age does not impact AMPK activity directly or affect AMPK
Figure 6. RNAi-mediated targeting of AMPK inhibits HCMV replication. MRC-5 fibroblasts were transfected with control or AMPK-specific
siRNA. Fibroblasts were then serum-starved at 48 h post transfection and subsequently mock or HCMV-infected 24 h later. (A) Samples were
harvested for Western blot analysis of AMPK knockdown. The RNAi-mediated percent reduction of AMPK expression from the relevant mock or
HCMV-infected control sample was estimated using densitometry. (B) At 48 h post infection, samples were harvested in lysis buffer and cellular
lysates were assayed for AMPK activity by measuring phosphorylation of the SAMS peptide by 32P-ATP. Results are shown as mean + SE (n = 3). (C) At
40 h post infection, fresh media was added to all cells. At 58 h post infection, media was removed from mock and HCMV-infected fibroblasts and
lactate secretion into the media over the 18 hr time frame was analyzed. All values are means + SE (n = 6). (D) At 96 h post infection, HCMV-infected
samples transfected with either control or AMPK-specific siRNA were harvested for viral plaque assay to measure viral replication. Results are shown
as mean + SE (n = 2).
doi:10.1371/journal.ppat.1002502.g006
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activation induced by another AMPK-activating kinase, LKB1
[19,40].
To further explore the impact of CaMKK inhibition on AMPK
activity, we examined the accumulation and phosphorylation of
AMPK and its substrates by Western blot after treatment with
STO-609. Pharmaceutical inhibition of CaMKK decreased the
levels of phosphorylated AMPK, but also reduced the levels of
total AMPK (Fig. 7B). Analysis of the relative ratio of phospho-
AMPK to total AMPK indicated STO-609 treatment shifted the
ratio towards the unphosphorylated AMPK by 30% at 24 hpi
(Fig. 7B). The observed reductions in total as well as pAMPK upon
STO-609 treatment likely contribute to the reduction in AMPK
activity observed in STO-609-treated cells (Fig. 7A). Analysis of
Ser79 phosphorylated-ACC upon STO-609 treatment indicated a
similar trend. The amounts of Ser79-phosphorylated ACC and
total ACC were both reduced upon STO-609 treatment, with a
reduction of 40-50% in the relative pACC/ACC ratio. Similar to
the observation with AMPK inhibition, treatment with STO-609
also blocked the increases in TSC1 and Glut4 levels observed
during HCMV-infection (Fig. 7B). As we had previously analyzed
the impact of STO-609 treatment on HCMV activated 13C-FBP
labeling [16], we wanted to extend these observations with respect
to measuring lactate production. Consistent with our previous 13C-
FBP labeling results, STO-609 treatment blocked the induction of
lactate secretion associated with HCMV infection yet had no effect
on the accumulation of lactate production in mock-infected cells
(Fig. 7C). Taken together, our results demonstrate that inhibition
of CaMKK inhibits HCMV-mediated AMPK activation as well as
the accumulation and phosphorylation of downstream AMPK
targets which is consistent with a model in which CaMKK
mediates AMPK activation during HCMV infection.
Discussion
We have previously established that HCMV infection induces
numerous changes to the host-cell metabolic network [13–14].
Induction of glycolysis has also been found to be critical for high-
titer HCMV replication [16,41]. Here we report that HCMV
activates AMPK, a metabolic stress kinase, and that HCMV
depends on its activity for high-titer replication. HCMV requires
AMPK activation to increase glucose import and drive increased
glycolytic flux (Fig. 8). Inhibition of AMPK attenuated both early
and late gene expression and markedly reduced viral DNA
replication. These results suggest that AMPK is an important
cellular factor for HCMV replication.
Unstressed, uninfected cells do not normally utilize AMPK to
activate glycolysis [17]. Our results support this view, as the
inhibition of AMPK did not impact the import of glucose or the
FBP labeling rate in uninfected cells (Fig. 3). In contrast to un-
infected cells, HCMV infection induces the activation of AMPK,
which is critical for HCMV-mediated glycolytic activation.
Figure 7. Impact of CaMKK inhibition on AMPK substrates.
Serum-starved MRC-5 human fibroblasts were mock infected or
infected with HCMV (MOI = 3). After adsorption, cells were treated with
the CaMKK inhibitor STO-609 (10 mg/ml) or DMSO (-). At 24, 48 and 72 h
post infection cells harvested in lysis buffer and the resulting lysates
were assayed for AMPK activity using the SAMS peptide as a substrate
(A) or analyzed by Western blotting with antibodies specific for Ser79-
pACC, ACC, TSC1, Glut4,Thr172-pAMPK, AMPK and tubulin (B). Relative
pACC/ACC and Thr172-pAMPK/AMPK signal ratios in (B) were estimated
during HCMV infection for DMSO and Compound C-treated cells using
densitometry and subsequently normalized to the DMSO control. (C) At
40 h post infection, fresh media was added to all cells. At 58 h post
infection, media was removed from mock and HCMV-infected
fibroblasts and lactate secretion into the media over the 18 hr time
frame was analyzed. All values are means + SE (n = 6).
doi:10.1371/journal.ppat.1002502.g007
Figure 8. Model of HCMV-mediated manipulation of the AMPK
pathway. HCMV infection results in AMPK activation, likely through
activation of CaMKK. AMPK activation results in glycolytic activation to
provide energy and building blocks necessary for production of viral
progeny. AMPK activation would typically result in inhibition of cellular
processes important for viral replication, e.g. protein translation and
fatty acid biosynthesis. Viral gene products block these consequences
of AMPK activation, e.g. UL38 binds TSC complex and prevents
inhibition of mTOR and protein translation. (FP = fructose-6-phosphate,
FBP = fructose-1,6-bisphosphate).
doi:10.1371/journal.ppat.1002502.g008
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Interestingly, activation of AMPK would be predicted to have
several consequences that are detrimental to infection including
inhibition of protein translation and fatty acid biosynthesis [42].
AMPK-mediated inhibition of translation occurs through induc-
tion of the TSC1/2 complex which in turn negatively regulates
translation through inhibition of mTOR [33–34]. It has recently
been shown that the HCMV UL38 protein can bind to the TSC1/
2 complex and prevent its inhibitory activity on mTOR and
translation initiation [31,43]. Taken together, it appears that
HCMV infection induces AMPK activation which in turn drives
glycolytic activation, yet blocks the anti-viral effects of AMPK
activation through the action of specific gene products such as
UL38 (Fig. 8).
While the UL38 protein appears sufficient to block the
inhibitory effects of AMPK activation on mTOR activity, it is
less clear how HCMV infection blocks AMPK’s inhibitory effects
on fatty acid biosynthesis. We have previously found that HCMV
induces fatty acid biosynthesis, and specifically induces the activity
of acetyl-CoA carboxylase (ACC), the rate-limiting enzyme of fatty
acid biosynthesis [14,29]. ACC, and consequently fatty acid
biosynthesis, is negatively regulated by activated AMPK [17].
Given that HCMV requires activated fatty acid biosynthesis and
ACC activity for viral replication, it is likely that HCMV infection
blocks the negative impact of activated AMPK on ACC activity,
potentially through the activity of an HCMV viral protein.
Our results suggest that inhibition of CaMKK blocks the down-
stream effects associated with activated AMPK (Fig. 7). Previous
reports suggest that pharmaceutical inhibition of CaMKK using
STO-609 blocks CaMKK-mediated activation of AMPK but does
not impact LKB1- mediated AMPK activation or activation of
AMPK upon energetic stress, for example, upon treatment with
glycolysis inhibitors [19,40]. Taken together, these results suggest
that HCMV infection requires CaMKK activity to activate
AMPK, though the exact mechanism responsible is unclear. Our
results suggest that inhibition of CaMKK reduces the amount of
Thr172-phosphorylated AMPK, a known CaMKK phosphoryla-
tion site, as well as the total amount of AMPK. Both of these
effects would be predicted to contribute to a decrease in AMPK
activity during HCMV infection. Other AMPK phosphorylation
sites have been implicated in the regulation of AMPK activity [35–
37], thus CaMKK could potentially be modulating AMPK activity
through phosphorylation of sites other than Thr172 as well.
We have previously reported that inhibition of CaMKK blocks
high-titer virus production [16]. Our current findings that AMPK
inhibition blocks HCMV replication to a similar extent as
CaMKK inhibition is consistent with a model in which HCMV-
mediates AMPK activation through CaMKK (Fig. 8). How
HCMV infection induces CaMKK activity still remains to be
determined, although it has previously been reported that HCMV
infection induces Ca2+ release from ER stores and we have found
that HCMV infection induces CaMKK expression [16,44], both
of which would be predicted to increase CaMKK activity.
Glycolysis has been shown to be important for HCMV re-
plication, and glycolytic inhibition has a similar impact on HCMV
as inhibition of AMPK and CaMKK [16,41]. The similarity is
both quantitative, in terms of the magnitude of reduction in viral
titers, as well as qualitative, in blocking viral DNA replication and
late gene expression, attenuating early gene expression and having
no detectable impact on immediate early gene expression [16,41].
Given these similarities, and combined with the observed necessity
of AMPK and CaMKK for HCMV-induced glycolysis, the
simplest model would be that CaMKK and AMPK activation
are important for HCMV replication due to their activation of
glycolysis. Despite these correlations, it remains to be determined
how much of HCMV’s reliance on CaMKK and AMPK activity is
due to their activation of glycolysis. The possibility that these
kinases contribute to viral infection through phosphorylation of
other cellular or viral targets cannot be ruled out.
In summary, we find that HCMV infection activates AMPK,
which is required for HCMV-mediated glycolytic activation and
high-titer HCMV replication. As AMPK activation signals
metabolic stress to normal cells, HCMV has evolved mechanisms
to block the anti-viral consequences of metabolic stress pathway
activation. While some of these mechanisms are known, such as
UL38 maintaining mTOR activation through interaction and
inhibition of the TSC complex, others remain to be elucidated,
such as maintenance of fatty acid biosynthesis. This stress response
balancing act is representative of a recurrent theme in virus-host
evolution. Replicating viruses must create a cellular environment
conducive to viral replication, the efforts of which host cells have
evolved to resist. In the case of AMPK, the evolutionary struggle is
for the keys to the host-cell metabolic machinery. As the AMPK
pathway is not normally activated in uninfected cells and
inhibition of AMPK activity is tolerated in animal models [45–
46], targeting this pathway clinically could be therapeutically
beneficial for preventing HCMV-associated disease.
Materials and Methods
Cell culture and virus infection
MRC-5 fibroblasts were cultured in Dulbecco modified Eagle
medium (DMEM; Invitrogen) supplemented with 7.5% fetal
bovine serum. Cells were grown to confluence in either 10 cm
or 6-well tissue culture plates. Once confluent, medium was re-
moved and serum-free DMEM was added. Cells were maintained
in serum-free medium for 24 h prior to infection.
HCMV (strain Ad169) was used to infect cells at a multiplicity of
infection (MOI) of 3 for all of the current experiments. Mock-
infected controls were treated with an equal volume of medium
containing the same serum concentrations as virus-treated cells.
Virus adsorptions were carried out for 90 min at 37uC, after which
viral innocula were aspirated and serum-free DMEM was added
back. Production of infectious virus was measured by standard
viral plaque assay.
Chemical reagents
STO-609 (EMD Biosciences), a specific inhibitor of CaMKK
and Compound C (Calbiochem), a specific inhibitor of AMPK,
were maintained in DMSO at concentrations of 5 mg/ml at
220uC and 10 mg/ml at 4uC, respectively.
Kinetic flux profiling
Labeled DMEM was prepared from glucose-free media by
adding 10 mM HEPES and either labeled (13C) or unlabelled
(12C) glucose to a final concentration of 4.5 gL-1. For flux analysis,
samples were switched to fresh, unlabelled medium 24 h and 1 h
before final addition of 13C-labeled medium. Samples were labeled
for 1 min and the reaction was quenched by the addition of 4 ml
280uC 80% methanol and incubation at 280uC for 10 minutes.
Cells were then scraped in the methanol, centrifuged at 3000 rpm
for 5 min at 4uC and the supernatant was collected. The pellet was
extracted twice more in 500 ml cold methanol, adding the resulting
supernatants to the previously collected supernatant. After
extraction, the supernatants were dried down under nitrogen gas
and resuspended in 175 ml of 50% methanol. Samples were
subsequently spun down at full speed for 5 min at 4uC and the
remaining supernatant was transferred to HPLC sample vials.
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Liquid chromatography-tandem mass spectrometry
analysis
The accumulation of fully-13C-labeled fructose 1,6-bispho-
sphate was monitored using liquid chromatography-tandem mass
spectrometry (LC-MS/MS) as previously described [14] and is
briefly discussed below. LC-MS/MS was performed using a LC-
20AD HPLC system (Shimadzu) and a Synergi Hydro-RP column
(15062 mm with a 5 mm-particle size; Phenomenex) coupled to a
mass spectrometer. The LC parameters were as follows:
autosampler temperature, 4uC; injection volume, 20 ml; column
temperature, 40uC; flow rate, 15 ml/sec. The LC solvents were
solvent A, 100% methanol; solvent B, 10 mM tributylamine and
15 mM acetic acid in 97:3 water:methanol. The gradient
conditions were as follows: negative mode—t = 0, 100% B; t = 5,
100% B; t = 10, 80% B; t = 20, 80% B; t = 35, 35% B; t = 38, 5%
B; t = 42, 5% B; t = 43, 100% B; t = 50, 100% B. Mass
spectrometric analyses were performed on a TSQ Quantum
Ultra triple-quadrupole mass spectrometer running in multiple
reaction monitoring mode (MRM) (Thermo Fisher Scientific).
Peak heights for fructose-1,6-bisphosphate-extracted ion chro-
matograms were analyzed using Excalibur software (Thermo
Fisher Scientific).
Western Blot analysis
Proteins from cell lysates were solubilized in 1X disruption
buffer (50 mM Tris (pH 7.0), 2% SDS, 5% 2-mercaptoethanol,
and 2.75% sucrose), separated by 10% SDS-PAGE and
transferred to nitrocellulose in Tris-glycine transfer buffer. Blots
were stained with Ponceau S to visualize protein and ensure equal
sample loading. The membranes were blocked in 5% milk in
TBST followed by incubation in primary antibody. After
subsequent washes, blots were incubated in secondary antibody
and protein bands were visualized using the ECL detection system
(Pierce). Antibodies used were specific for the following viral
proteins: IE1 (Shenk Laboratory, unpublished), UL44 (Virusys),
and pp28 [47] and the following cellular proteins: tubulin
(Epitomics), TSC1 (Millipore), Glut4 (Abcam), ACC and phos-
phor-Ser79-ACC (Cell Signaling Technologies), AMPK and
phospho-Thr172-AMPK (Cell Signaling Technologies). Image
densitometry of specific protein bands was performed with ImageJ,
developed by Rasband, W.S. at the NIH (http://imagej.nih.gov/
ij/), as per the ImageJ instructions.
AMPK activity assay
AMPK was assayed largely as previously described [27]. Briefly,
cells were washed 3X with warm Krebs-Hepes buffer (20 mM Na
Hepes, pH 7.4, 118 mM NaCl, 3.5 mM KCl, 1.3 mM CaCl2, 1.2
MgSO4, 10 mM glucose, 1.2 mM KH2PO4, 0.1% BSA) and
incubated in Krebs-Hepes buffer containing either DMSO, the
AMPK inhibitor, Compound C (5 mM), for 1 h at 37uC, or the
CaMKK inhibitor, STO-609 (10 mg/ml). Buffer was then
aspirated and dishes were placed on ice with immediate addition
of 0.25 ml ice-cold lysis buffer (50 mM Tris/HCl, pH 7.4, 50 mM
NaF, 5 mM Na pyrophosphate, 1 mM EDTA, 1 mM EGTA,
250 mM mannitol, 1% Triton X-100, 1 mM DTT, protease
inhibitors). Cells were scraped and the resulting lysates transferred
to microfuge tubes and incubated on ice for 10 minutes. Lysates
were then centrifuged for 5 min at 14000 xg and 4uC in
preparation for use.
The AMPK assay was composed of a total reaction volume of
25 ml that was incubated for 10 min at 30uC. Each reaction
consisted of 2.5 ml lysate assay buffer (62.5 mM Na Hepes, pH 7.0,
62.5 mM NaCl, 62.5 mM NaF, 6.25 mM Na pyrophosphate,
1.25 mM EDTA, 1.25 mM EGTA, 1 mM DTT, and protease
inhibitor cocktail (Roche)), 2.5 ml of 100 mM [c-32P]-ATP (1 mCi/
ml) in 25 mM MgCl2, 2.5 ml of 2 mM AMP in lysate assay buffer,
5 ml of 1 mM SAMS peptide in lysate assay buffer, with either
Compound C (5 mM final) or the equivalent volume of DMSO and
12.5 ml cell lysate. The reaction mixture was spotted on P81
phosphocellulose paper which was washed with 1% phosphoric
acid, water, and acetone. The radioactivity of the phosphorylated
SAMS peptide was quantified by scintillation counting. Non-
AMPK-mediated phosphorylation of the SAMS peptide was
estimated by performing the AMPK activity assay in the presence
of saturating amounts of the AMPK inhibitor, Compound C.
siRNA experiments
MRC-5 fibroblasts were transfected with 150 pmol of either
esiRNA (pooled endoribonuclease-prepared siRNA) specific to
AMPK1 (Sigma-Aldrich) or a non-targeting siRNA (Dharmacon)
using Oligofectamine per manufacturer’s directions. Forty-eight
hours after transfection, siRNA-transfected cells were serum-
starved for 24 h and then either mock-infected or infected with
HCMV (MOI = 3). Samples were harvested at 24 h and 72 h
post-infection to monitor AMPK protein knockdown by Western
blot. Additional samples were harvested 96 h post-infection to
monitor viral titers by standard plaque assay.
Real-time PCR
Viral and cellular DNA was harvested at various time points post-
infection in lysis buffer (100 mM NaCl, 100 mM Tris-HCl, 25 mM
EDTA, 0.5% SDS, 0.1 mg/ml proteinase K and 40 mg/ml RNase
A), and viral DNA was quantified using the UL26 primer set
(below). Quantitative PCR (qPCR) was performed using Fast SYBR
green master mix, a model 7500 Fast real-time PCR system and
Fast 7500 software (Applied Biosystems). For quantifying viral DNA
aUL26-HCMV specific primer set was employed: 5_-AACAT-
CGCGTCGGTGATTTCTTGC-3_ (forward) and 5_-ACAGC-
TACTTTGAAGACGTGGAGC-3_ (reverse), GAPDH 5_-CAT-
GTTCGTCATGGGTGTGAACCA-3_ (forward) and 5_-ATG-
GCATGGACTGTGGTCATGAGT-3_ (reverse).
Lactate measurement
Lactate was measured in media samples using the BioProfile 100
Plus/400 (Nova Biomedical), which employs an enzyme dependent
amperometric electrode. MRC-5 fibroblasts were cultured in serum
free DMEM for 24 h before infection and either mock or HCMV-
infected. Lactate excretion into the media was measured over an 18
h interval, starting with a media change. After 18 h, 600 ml of media
was removed from each sample dish and analyzed according to the
manufacturer’s instructions (Nova Biomedical).
Gene identification information
Further information regarding the genes/ proteins studied in
this manuscript can be found at the NCBI Gene Database (http://
www.ncbi.nlm.nih.gov/gene). Specific database entries for cellular
genes are as follows: AMPK = PRKAB1, PRKAA1, PRKAG1;
CaMKK = CAMKK1, CAMKK2; TSC1 = TSC1; TSC2 =
TSC2; Glut4 = SLC2A4; ACC1 = ACACA. The viral genes
mentioned include the following from HCMV (also known as
Human Herpesvirus 5): UL38 = UL38; IE1 = UL123; UL44 =
UL44; pp28 = UL99.
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